Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 623
Filter
1.
Arch. argent. pediatr ; 122(4): e202310173, ago. 2024. tab
Article in English, Spanish | LILACS, BINACIS | ID: biblio-1562714

ABSTRACT

Introducción. La rinitis alérgica (RA) es una de las enfermedades crónicas más frecuentes en la población pediátrica, afecta la calidad de vida del niño y la familia, tiene impacto económico y es frecuentemente subdiagnosticada y subtratada. Dada la escasez de datos locales, se describe su prevalencia y las características clínicas de la población en estudio. Población y métodos. Estudio observacional de corte transversal de pacientes menores de 19 años. Resultados. Se incluyeron 250 pacientes al azar, con una media de edad de 9 años (DE 5) Presentaron diagnóstico de RA 14 de ellos; se observó una prevalencia de RA del 6 %. Conclusiones. La prevalencia de RA en nuestro medio es del 6 %. Debemos darle la relevancia que amerita para brindar un diagnóstico y tratamiento adecuado.


Introduction. Allergic rhinitis (AR) is one of the most frequent chronic diseases in the pediatric population; it affects the quality of life of children and their families, has economic impact, and is frequently underdiagnosed and undertreated. Given the scarcity of local data, here we describe the prevalence of AR and the clinical characteristics of the study population. Population and methods. Observational, cross-sectional study in patients younger than 19 years. Results. A total of 250 patients were randomly included; their mean age was 9 years (SD: 5). AR was diagnosed in 14 of them. The prevalence of AR was 6%. Conclusions. The prevalence of AR in our setting was 6%. AR should be given the relevance it deserves so as to provide an adequate diagnosis and treatment.


Subject(s)
Humans , Male , Female , Child, Preschool , Child , Adolescent , Rhinitis, Allergic/diagnosis , Rhinitis, Allergic/epidemiology , Hospitals, General , Pediatrics , Prevalence , Cross-Sectional Studies , Hospital Departments/statistics & numerical data
2.
Arq. Asma, Alerg. Imunol ; 8(2): 129-138, 20240600. Ilus
Article in English, Portuguese | LILACS | ID: biblio-1585260

ABSTRACT

Objective: To describe the efficacy and safety of house dust mite sublingual immunotherapy (SLIT) in patients with allergic rhinitis (AR) over a 12-month period. Methods: This is a prospective, open-label study of children and adolescents aged 4 to 18 years with AR/asthma according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines, followed up at the outpatient clinics of the Hospital de Clínicas affiliated with the Federal University of Paraná, southern Brazil. All patients received SLIT drops (750 UBE/day) for Dermatophagoides pteronyssinus (DP) and Blomia tropicalis (BLO) at a concentration of 5000 UBE/mL for 12 months. Symptom and medication scores (RTSS) were assessed and skin prick tests for aeroallergens were performed from January 2022 to January 2023. Results: Twenty participants with an AR diagnosis for at least 4 years (range, 2-10) were included. The mean SLIT adherence rate was 89%. The mean DP wheal diameter reduced from 7.0 (SD 2.9) to 4.2 (SD 2.1) mm after 12 months (p=0.0002), while the median BLO wheal diameter reduced from 3.7 to 3.0 mm (p=0.0001). Patients showed a reduction in rescue medication use, symptom score, and combined symptom and medication scores (p<0.05). The mean visual analog scale score reduced from 9.3 (SD 0.7) to 5.2 (SD 1.4) (p<0.05). There was no difference in asthma control (p=0.16). The rate of mild adverse effects was low and did not differ throughout the study (p=0.62). There were no anaphylactic reactions. Conclusion: SLIT may provide short-term benefits to patients with AR, reducing the need for medication and improving nasal symptoms. SLIT was well tolerated and safe, with no serious adverse events.


Objetivo: Descrever a eficácia e segurança da imunoterapia com alérgenos sublingual (SLIT) com ácaros em pacientes com rinite alérgica durante um período de 12 meses. Métodos: Estudo experimental aberto, prospectivo que envolveu crianças e adolescentes de 4 a 18 anos com rinite alérgica/asma segundo as diretrizes Allergic Rhinitis and its Impact on Asthma (ARIA), acompanhados nos ambulatórios do Hospital de Clínicas da Universidade Federal do Paraná. Todos os pacientes receberam gotas (750 UBE/dia) de SLIT para Dermatophagoides pteronyssinus (DP) e Blomia tropicalis (BLO) na concentração de 5.000 UBE/mL durante 12 meses. Foram aplicados escores de medicação (RTSS), testes cutâneos para aeroalérgenos entre janeiro de 2022 e janeiro de 2023. Resultados: Vinte participantes com pelo menos 4 (variação de 2 a 10) anos de diagnóstico de RA. A adesão média à SLIT foi de 89%. Houve redução no diâmetro médio da pápula DP de 7 ± 2,9 mm para 4,2 ± 2,1 mm após 12 meses (p = 0,0002), bem como na mediana do diâmetro médio da pápula BLO de 3,7 mm a 3 mm (p = 0,0001). Os pacientes apresentaram redução no consumo de medicamentos de resgate, no escore de sintomas e no escore combinado de sintomas e medicamentos (p < 0,05). A pontuação da escala visual analógica reduziu de 9,3 ± 0,7 para 5,2 ± 1,4 ao final do estudo (p < 0,05). Não houve diferença no controle da asma (p = 0,16). A taxa de efeitos adversos leves foi baixa e não diferiu ao longo do estudo (p = 0,62), e não houve reações anafiláticas. Conclusão: A SLIT pode trazer benefícios em curto prazo em pacientes com RA, reduzindo a necessidade de medicação e melhorando os sintomas nasais. Foi bem tolerada e segura, sem eventos adversos graves.


Subject(s)
Humans , Child, Preschool , Child , Adolescent , Safety , Efficacy , Dermatophagoides pteronyssinus , Sublingual Immunotherapy , Rhinitis, Allergic , Mites , Asthma
3.
Arq. Asma, Alerg. Imunol ; 8(2): 162-165, 20240600. Ilus
Article in English, Portuguese | LILACS | ID: biblio-1585277

ABSTRACT

A rinite alérgica local (RAL) é um fenótipo de rinite definido recentemente e seu diagnóstico configura um grande desafio tanto para médicos, como para os seus pacientes. A RAL não apresenta evidências de sensibilização sistêmica e, por essa razão, é frequentemente classificada de forma inadequada como uma rinite não alérgica. Este fenótipo de rinite apresenta resposta inflamatória alérgica T2 nasal e síntese local de IgE específica, sendo que o teste de provocação nasal específico é considerado o método padrão ouro para realizar o seu diagnóstico. A RAL possui características clínicas semelhantes aos outros fenótipos de rinite, e pela dificuldade diagnóstica é subdiagnosticada em todas as faixas etárias. O diagnóstico fenotípico correto da rinite tem potenciais benefícios para os pacientes, não apenas por possibilitar a implementação de cuidados para a redução da exposição ambiental aos alérgenos identificados, mas principalmente por permitir a realização de imunoterapia alérgeno específica.


Local allergic rhinitis (LAR) is a recently defined rhinitis phenotype, and its diagnosis represents a major challenge for both physicians and patients. LAR shows no evidence of systemic sensitization and is therefore often inappropriately classified as non-allergic rhinitis. This rhinitis phenotype shows a nasal T2 allergic inflammatory response and local IgE synthesis, and nasal allergen challenge is considered the gold standard method for its diagnosis. LAR has clinical features similar to those of other rhinitis phenotypes, and due to diagnostic difficulties, it is underdiagnosed in all age groups. The correct phenotypic diagnosis of LAR offers potential benefits for patients not only by enabling the implementation of care to reduce environmental exposure to identified allergens, but mainly by allowing allergen-specific immunotherapy.


Subject(s)
Humans , Male , Adolescent , Sublingual Immunotherapy , Rhinitis, Allergic , Therapeutics , Immunoglobulin E , Allergens , Immunotherapy
4.
Respirar (Ciudad Autón. B. Aires) ; 16(1): 79-83, Marzo 2024.
Article in Spanish | LILACS, UNISALUD, BINACIS | ID: biblio-1551228

ABSTRACT

Se presenta el caso de un niño de 3 años con diagnóstico de asma, rinitis alérgica, características craneofaciales dismórficas e infecciones respiratorias altas y bajas recurrentes, manejado como asma desde un inicio. Como parte del estudio de comorbilidades, se decide realizar una prueba del sudor que sale en rango intermedio y más tarde se encuentra una mutación, donde se obtiene un resultado positivo para una copia que se asocia a fibrosis quística. Se revisará el caso, así como el diagnóstico, clínica y tratamiento del síndrome metabólico relacionado con el regulador de conductancia transmembrana de fibrosis quística (CRMS).


We present the case of a 3-year-old boy with a diagnosis of asthma, allergic rhinitis, dysmorphic craniofacial characteristics and recurrent upper and lower respiratory infections, managed as asthma from the beginning. As part of the study of comorbidi-ties, it was decided to carry out a sweat test that came out in the intermediate range and later one mutation was found, where a positive result was obtained for a copy that is associated with cystic fibrosis. The case will be reviewed, as well as the diagnosis, symptoms and treatment of the metabolic syndrome related to the cystic fibrosis trans-membrane conductance regulator (CRMS).


Subject(s)
Humans , Male , Child, Preschool , Asthma/diagnosis , Respiratory Sounds/diagnosis , Cough/diagnosis , Cystic Fibrosis/diagnosis , Metabolic Syndrome/diagnosis , Rhinitis, Allergic/diagnosis , Respiratory Tract Infections , Radiography, Thoracic , Comorbidity , Neonatal Screening , Cystic Fibrosis Transmembrane Conductance Regulator/genetics
5.
Rev. cuba. med. mil ; 52(3)sept. 2023. tab
Article in English | LILACS, CUMED | ID: biblio-1559840

ABSTRACT

Introduction: Monitoring changes in the levels of immune markers is of great significance in evaluating the effectiveness of treatment in patients with allergic rhinitis. Objectives: Determine the change in the concentration of immune markers after treatment in patients with allergic rhinitis caused by cotton dust. Methods: A descriptive, single-group, comparative before and after intervention study on 52 patients with allergic rhinitis caused by cotton dust. Comparison of immunological markers results before and after 36 months of treatment. Results: Total IgE concentration after treatment decreased, the median decreased from 1227.756 U/mL to 676.805 UI/mL. Serum levels of IgG, IgG4, and IgG1 in patients after treatment increased compared to before (p< 0.001). The cytokines also changed in the direction of no longer responding toward allergy. Median IL-17 decreased from 1.752 mg/dL to 0.417 mg/dL. Conclusion: In patients with allergic rhinitis after specific sublingual desensitization treatment, IgE levels and cytokines such as IL-6 and IL-17 are significantly reduced and IgG, IgG4 and IgG1 levels are increased after treatment(AU)


Introducción: El monitoreo de los cambios en los niveles de marcadores inmunes es de gran importancia para evaluar la efectividad del tratamiento en pacientes con rinitis alérgica. Objetivos: Determinar el cambio en la concentración de marcadores inmunes después del tratamiento, en pacientes con rinitis alérgica causada por polvo de algodón. Métodos: Estudio descriptivo, monogrupo, comparativo antes y después de la intervención, en 52 pacientes con rinitis alérgica por polvo de algodón. Se compararon resultados de marcadores inmunológicos antes y después de 36 meses de tratamiento. Resultados: La concentración de IgE total después del tratamiento disminuyó, la mediana disminuyó de 1227,756 U/mL a 676,805 UI/mL. Los niveles séricos de IgG, IgG4 e IgG1 en pacientes, después del tratamiento, aumentaron (p< 0,001). Las citocinas también cambiaron en dirección a ausencia de respuesta a la alergia. La mediana de IL-17 disminuyó de 1,752 mg/dL a 0,417 mg/dL. Conclusión: En pacientes con rinitis alérgica, después del tratamiento específico de desensibilización sublingual, los niveles de IgE y citocinas como IL-6 e IL-17 se reducen significativamente y los niveles de IgG, IgG4 e IgG1 aumentan(AU)


Subject(s)
Humans , Immunoglobulin E , Immunoglobulin G , Biomarkers , Treatment Outcome , Dust , Antigens, Plant , Rhinitis, Allergic/therapy , Administration, Sublingual , Cytokines/immunology , Clothing , Adrenal Cortex Hormones/therapeutic use , Gossypium , Drug Evaluation/methods , Histamine Antagonists/therapeutic use , Occupational Groups
6.
Braz. j. otorhinolaryngol. (Impr.) ; Braz. j. otorhinolaryngol. (Impr.);89(2): 235-243, March-Apr. 2023. tab, graf
Article in English | LILACS | ID: biblio-1439730

ABSTRACT

Abstract Objective: We aimed to evaluate the effect of radiofrequency turbinate reduction as an initial treatment on clinical improvement, inflammatory mediators, and remodeling process. Methods: Between July 2018- February 2020, 32 patients with moderate-severe persistent AR were randomly divided into 2 groups. Intervention group received radiofrequency turbinate reduction followed by intranasal steroid and Antihistamine H-1 (AH-1), control group received intranasal steroid and AH-1. Both groups were evaluated for clinical improvement (using visual analogue scale based on total nasal symptoms score, peak nasal inspiratory flow, and turbinate size using imageJ) after 4 and 8 weeks of treatment. Inflammatory mediators (ELISA from nasal secretions was performed to measure ECP, IL-5, and HSP-70) and remodeling markers (nasal biopsy followed by immunohistochemistry examination was performed to evaluate MMP-9, TIMP-1, and PAI-1) were evaluated in week 4. Results: Three patients dropped out of the study, resulting in 16 patients in intervention group and 13 patients in control group. At week 4, clinical response improved significantly in the intervention group compared to control group (Chi-Square test, p<0.05). Compared to control, intervention group experienced a reduction of IL-5 and no significant change in ECP level (Mann Whitney test, p>0.05). Reduction in the ratio of MMP-9/TIMP-1 were significantly higher in intervention group (unpaired t-test, p< 0,05). Meanwhile, increase in HSP-70 in the intervention group was slightly lower than in control group, but the difference with control group was not significant (Mann Whitney test, p>0.05). Conclusion: Early radiofrequency turbinate reduction followed by pharmacotherapy given to persistent moderate-severe AR patients give more improvement only in early clinical symptoms and reduce MMP-9/TIMP-1 ratio, thus it might be suggested as one of the adjuvant therapies for the management of moderate-severe persistent AR. However, further investigation with a larger sample size and longer follow-up period is needed. Level of evidence: 1B.


Subject(s)
Turbinates/surgery , Turbinates/pathology , Rhinitis, Allergic/drug therapy , Steroids , Administration, Intranasal , Interleukin-5/therapeutic use , Treatment Outcome , Tissue Inhibitor of Metalloproteinase-1/therapeutic use , Matrix Metalloproteinase 9 , Histamine Antagonists/therapeutic use
7.
Arch. argent. pediatr ; 121(2): e202202894, abr. 2023. tab
Article in Spanish | LILACS, BINACIS | ID: biblio-1425155

ABSTRACT

La rinitis alérgica (RA) es una de las enfermedades crónicas más frecuentes de la infancia. Sin embargo, permanece subdiagnosticada y subtratada. Su prevalencia ha aumentado en los últimos años y varía del 2 % al 25 %. Los síntomas de la RA incluyen estornudos, prurito, rinorrea y congestión nasal. Un correcto diagnóstico y tratamiento de la RA y sus comorbilidades, tales como rinosinusitis con o sin poliposis nasal, conjuntivitis, otitis media, asma bronquial e infecciones del tracto respiratorio, son importantes para reducir el impacto negativo en la afectación de la calidad de vida del paciente y sus familiares, y los gastos sanitarios que ocasiona. La inmunoterapia alérgeno específica, en pacientes correctamente seleccionados, previene nuevas sensibilizaciones y reduce la hiperreactividad bronquial asociada a la RA. Considerando todos estos factores, el Comité Nacional de Alergia de la Sociedad Argentina de Pediatría propone recomendaciones basadas en la evidencia actual.


Allergic rhinitis (AR) is one of the most common chronic diseases in children. However, it remains underdiagnosed and undertreated. Its prevalence has increased in recent years and varies from 2 to 25 %. Symptoms include sneezing, itching, runny nose, and nasal congestion. A correct diagnosis and treatment of AR and its comorbidities such as rhinosinusitis with or without nasal polyposis, conjunctivitis, otitis media, bronchial asthma and respiratory tract infections, are important to reduce the negative impact on the quality of life of the patient and their relatives, and in medical costs. Specific allergen immunotherapy, in correctly selected patients, prevents new sensitizations and reduces bronchial hyperreactivity associated with AR. Taking into account all these reasons, the National Allergy Committee of the Sociedad Argentina de Pediatría proposes current evidence based recommendations


Subject(s)
Humans , Child , Pediatrics , Asthma/complications , Rhinitis/complications , Rhinitis, Allergic, Perennial/diagnosis , Rhinitis, Allergic, Perennial/therapy , Rhinitis, Allergic, Perennial/epidemiology , Rhinitis, Allergic/diagnosis , Rhinitis, Allergic/therapy , Rhinitis, Allergic/epidemiology , Quality of Life
8.
Rev. am. med. respir ; 23(1): 7-15, mar. 2023. graf
Article in Spanish | LILACS, BINACIS | ID: biblio-1514915

ABSTRACT

Objetivo: El objetivo del presente estudio fue evaluar la eficacia y seguridad de la combinación de dosis fija montelukast/desloratadina 10mg/5mg cápsula versus la combinación de montelukast/loratadina 10 mg/10 mg tableta en adultos con diagnóstico de rinitis alérgica persistente. Material y métodos: El presente fue un estudio clínico aleatorizado, controlado, doble ciego, prospectivo, longitudinal, multicéntrico, con brazos paralelos. Sujetos con diag nóstico de rinitis alérgica persistente que cumplieran criterios de elegibilidad y firmaran consentimiento informado fueron enrolados para recibir uno de los dos tratamientos cada 24 horas vía oral durante 6 semanas. La eficacia se estableció mediante la evaluación clínica a través de escalas clínicas validadas en idioma español, siendo la variable primaria de eficacia la diferencia de puntuación del cuestionario SNOT-20 al final del tratamiento, mientras que la frecuencia y características de los eventos adversos fue considerada la variable de seguridad. Resultados: Se aleatorizaron 86 pacientes, 74 de ellos fueron analizados por protocolo. Los cuestionarios sobre síntomas de la enfermedad e indicadores de calidad de vida con ambos tratamientos mostraron que más del 90% de los pacientes no presentaron síntomas o solo fueron leves al final del estudio, por lo que ambos tratamientos me joraron significativamente (p < 0.05) la sintomatología de la enfermedad. Los eventos adversos presentados fueron leves a moderados. Conclusiones: El presente estudio demostró que la eficacia de montelukast/deslora tadina 10mg/5mg no es inferior al medicamento comparador. Por tanto, el tratamiento de prueba representa una alternativa eficaz y segura para el tratamiento de segunda línea de la rinitis alérgica persistente en pacientes que las monoterapias o primeras líneas de tratamiento no ofrecen mejoría clínicamente relevante.


Objective: The objective of the present study was to evaluate the efficacy and safety of the fixed dose combination of montelukast/desloratadine 10 mg/5 mg capsule versus the combination of montelukast/loratadine 10 mg/10 mg tablet in adults diagnosed with persistent allergic rhinitis. Materials and methods: The present study was a multicenter, controlled, prospective, longitudinal, randomized, double-blind clinical trial with parallel arms. Patients diagnosed with persistent allergic rhinitis who met eligibility criteria and signed informed consent were enrolled in the study to receive one of the two treatments every 24 hours orally for 6 weeks. Efficacy was established by clinical evaluation through clinical scales vali dated in Spanish, being the primary efficacy variable the difference in the score of the SNOT-20 (Sino-Nasal Outcome Test) questionnaire at the end of treatment; and the frequency and characteristics of adverse events were considered the safety variable. Results: 86 patients were randomized, 74 of which were analyzed per protocol. Ques tionnaires about the symptoms of the disease and quality of life indicators with both treatments showed that more than 90% of patients had mild symptoms or no symptoms at all at the end of the study. So, both treatments significantly improved (p < 0.05) the symptoms of the disease. Adverse events were mild to moderate. Conclusions: The present study showed that the efficacy of montelukast/desloratadine 10 mg/5 mg is not inferior to the comparator. Therefore, the study treatment represents an effective and safe alternative for the second-line treatment of persistent allergic rhinitis in patients in whom monotherapies or first-line treatments don't offer clinically relevant improvement.


Subject(s)
Rhinitis, Allergic
9.
Article in Chinese | WPRIM | ID: wpr-986948

ABSTRACT

Objective: To explore the effect of vidian neurectomy and selective vidian neurectomy in the treatment of moderate and severe persistent allergic rhinitis (AR). Methods: A total of 60 patients with moderate-to-severe persistent AR treated in Zhejiang Provincial Hospital of Integrated Traditional Chinese and Western Medicine from June 2018 to June 2020 were selected, including 28 males and 32 females. A total of 40 cases in the observation group were subjected to vidianneurectomy, while, 20 cases in the control group underwent selective vidianneurectomy. Patients in the two groups were followed up at 6 months, 1 year, and 2 years, respectively, and evaluated according to AR diagnostic and efficacy assessment criteria. Four symptoms of sneezing, clear runny nose, nasal congestion, and nasal itching were scored as efficacy indices before and at 6 months, 1 year, and 2 years after surgery. The regression of the lower turbinate swelling after surgery was assessed by nasal endoscopy or sinus CT. Postoperative tear secretion was followed up in both groups, and patients with dry eyes were counted in combination with ocular symptoms. SPSS 19.0 software was used to statistically analyze the data before and after the surgery and between the two groups. Results: The preoperative, 6-month, 1-year, and 2-year postoperative inferior turbinate signs were (2.73±0.45), (1.20±0.41), (1.25±0.49) and (1.30±0.56) points in the observation group and (2.75±0.44), (1.45±0.69), (1.75±0.72) and (1.90±0.85) points in the control group, respectively, with a statistically significant difference in the between-subjects effect test between the two groups (F=8.28, P<0.05), indicating a more durable surgical effect in the observation group. The total effective rate at 2 years after surgery was 95.0% (38/40) in the observation group and 50% (10/20) in the control group. The difference between the two groups by Fisher's exact test was statistically significant. No dry eye patient was found in either group at a 1.5-year postoperative follow-up. Conclusion: Both vidianneurectomy and selective vidianneurectomy have good recent treatment effects, vidianneurectomy has better long-term curative effects than selective vidianneurectomy.


Subject(s)
Male , Female , Humans , Treatment Outcome , Rhinitis, Allergic/surgery , Turbinates/surgery , Denervation , Nose Diseases
10.
Zhonghua Yu Fang Yi Xue Za Zhi ; (12): 273-280, 2023.
Article in Chinese | WPRIM | ID: wpr-969878

ABSTRACT

Objective: To investigate the clinical efficacy and safety of anti-IgE monoclonal antibody (omazumab) in the treatment of allergic united airway disease (UAD) in the real-wold. Methods: Retrospective cohort study summarizes the case data of patients with allergic united airway disease who were treated with anti IgE monoclonal antibody (omalizumab) for more than 16 weeks from March 1, 2018 to June 30, 2022 in the Peking University First Hospital.The allergic UAD is defined as allergic asthma combined with allergic rhinitis (AA+AR) or allergic asthma combined with chronic sinusitis with nasal polyps (AA+CRSwNP) or allergic asthma combined with allergic rhinitis and nasal polyps (AA+AR+CRSwNP). The control of asthma was evaluated by asthma control test (ACT), lung function test and fractional exhaled nitric oxide (FeNO). The AR was assessed by total nasal symptom score (TNSS). The CRSwNP was evaluated by nasal visual analogue scale (n-VAS), sino-nasal outcome test-22 (SNOT-22), nasal polyps score (TPS) and Lund-Mackay sinus CT grading system. The global evaluation of omalizumab for the treatment of allergic UADwas performed by Global Evaluation of Treatment Effectiveness(GETE).The drug-related side effects were also recorded. Matched t test and Wilcoxon signed-rank test were used to compare the score changes of IgE monoclonal antibody (omazumab) before and after treatment, and multivariate logistic regression analysis was used to determine the influencing factors of IgE monoclonal antibody (omazumab) response. Results: A total of 117 patients with UAD were enrolled, ranging in age from 19 to 77 years; The median age of patients was 48.7 years; Among them, 60 were male, ranging from 19 to 77 years old, with a median age of 49.9 years; There were 57 females, ranging from 19 to 68 years old, with a median age of 47.2 years. There were 32 cases in AA+AR subgroup, 59 cases in AA+CRSwNP subgroup, and 26 cases in AA+AR+CRSwNP subgroup. The total serum IgE level was 190.5 (103.8,391.3) IU/ml. The treatment course of anti IgE monoclonal antibody was 24 (16, 32) weeks. Compared with pre-treatment, omalizumab increased ACT from 20.0 (19.5,22.0) to 24.0 (23.0,25.0) (Z=-8.537, P<0.001), increased pre-bronchodilator FEV1 from 90.2 (74.8,103.0)% predicted value to 95.4 (83.2,106.0)% predicted value (Z=-5.315,P<0.001), increased FEV1/FVC from 80.20 (66.83,88.38)% to 82.72 (71.26,92.25)% (Z=-4.483,P<0.001), decreased FeNO from(49.1±24.8) ppb to (32.8±24.4) ppb (t=5.235, P<0.001), decreased TNSS from (6.5±2.6)to (2.4±1.9) (t=14.171, P<0.001), decreased n-VAS from (6.8±1.2) to (3.4±2.0)(t=14.448, P<0.001), decreased SNOT-22 from (40.0±7.9) to (21.3±10.2)(t=15.360, P<0.001), decreased TPS from (4.1±0.8) to (2.4±1.0)(t=14.718, P<0.001) and decreased Lund-Mackay CT score from (6.0±1.3) to (3.1±1.6)(t=17.012, P<0.001). The global response rate to omalizumab was 67.5%(79/117). The response rate in AA+AR (90.6%,29/32) was significantly higher than that in AA+CRSwNP (61.0%,36/59) and AA+AR+CRSwNP (53.8%,14/26) subgroups (χ2=11.144,P=0.004). Only 4 patients (3.4%,4/117) had mild side effects. Conclusion: The real-world study showed favorable effectiveness and safety of anti-IgE monoclonal antibody for treatment of allergic UAD. To provide basis for preventing the progress and precise treatment of allergic UAD.


Subject(s)
Female , Humans , Male , Middle Aged , Young Adult , Adult , Aged , Nasal Polyps/drug therapy , Omalizumab/therapeutic use , Rhinitis/drug therapy , Retrospective Studies , Asthma/diagnosis , Rhinitis, Allergic/drug therapy , Sinusitis/drug therapy , Antibodies, Monoclonal/therapeutic use , Chronic Disease
11.
Zhonghua Yu Fang Yi Xue Za Zhi ; (12): 318-326, 2023.
Article in Chinese | WPRIM | ID: wpr-969893

ABSTRACT

The almost all guidelines of allergic rhinitis (AR) diagnosis and treatment in the world agree the strategy of "combination of prevention and treatment, four in one". There are more descriptions about anti-allergic medications and allergen immunotherapy (AIT), but less contents of environmental control and health education. It is necessary to emphasize again that clinicians must attach great importance to environmental control and strengthen health education in order to realize the three-level prevention of AR and reduce its harm.


Subject(s)
Humans , Rhinitis, Allergic/prevention & control , Desensitization, Immunologic/methods
12.
Zhongguo zhenjiu ; (12): 123-127, 2023.
Article in Chinese | WPRIM | ID: wpr-969959

ABSTRACT

OBJECTIVE@#To observe the clinical efficacy of acupuncture for prevention of moderate to severe seasonal allergic rhinitis.@*METHODS@#A total of 105 patients with moderate to severe seasonal allergic rhinitis were randomly divided into an observation group (53 cases, 3 cases dropped off) and a control group (52 cases, 4 cases dropped off). The patients in the observation group were treated with acupuncture at Yintang (GV 24+), Yingxiang (LI 20), Hegu (LI 4), Zusanli (ST 36), Fengchi (GB 20), Feishu (BL 13), etc. 4 weeks before the seizure period, once every other day, 3 times a week for 4 weeks. The patients in the control group were not given any intervention before the seizure period. Emergency drugs can be given appropriately during the seizure period in both groups. After seizure period, the seizure rate was recorded in the two groups; before treatment and on week 1, 2, 4, 6 of seizure period after treatment, the rhinoconjunctivitis quality of life questionnaire (RQLQ) score and total nasal symptom score (TNSS) were observed in the two groups; the rescue medication score (RMS) was recorded on week 1-6 of seizure period in the two groups.@*RESULTS@#The seizure rate of the observation group was 84.0% (42/50), which was lower than 100.0% (48/48) in the control group (P<0.05). After treatment, the scores of RQLQ and TNSS at each time point of seizure period were decreased compared with before treatment in the observation group (P<0.01), which were lower than the control group (P<0.01). The RMS score at each time point of seizure period in the observation group was lower than the control group (P<0.05, P<0.01).@*CONCLUSION@#Acupuncture can reduce the incidence of moderate to severe seasonal allergic rhinitis, relieve the symptoms, improve the quality of life and reduce the use of emergency drugs.


Subject(s)
Humans , Rhinitis, Allergic, Seasonal , Rhinitis, Allergic/therapy , Quality of Life , Acupuncture Therapy , Acupuncture Points , Treatment Outcome , Seizures
13.
Article in Chinese | WPRIM | ID: wpr-971526

ABSTRACT

OBJECTIVE@#To investigate the changes in percentage of GATA3+ regulatory T (Treg) cells in patients with allergic rhinitis (AR) and mouse models.@*METHODS@#The nasal mucosa specimens were obtained from 6 AR patients and 6 control patients for detection of nasal mucosal inflammation. Peripheral blood mononuclear cells (PBMC) were collected from 12 AP patients and 12 control patients to determine the percentages of Treg cells and GATA3+ Treg cells. In a C57BL/6 mouse model of AR, the AR symptom score, peripheral blood OVA-sIgE level, and nasal mucosal inflammation were assessed, and the spleen of mice was collected for detecting the percentages of Treg cells and GATA3+ Treg cells and the expressions of Th2 cytokines.@*RESULTS@#Compared with the control patients, AR patients showed significantly increased eosinophil infiltration and goblet cell proliferation in the nasal mucosa (P < 0.01) and decreased percentages of Treg cells and GATA3+ Treg cells (P < 0.05). The mouse models of AR also had more obvious allergic symptoms, significantly increased OVA-sIgE level in peripheral blood, eosinophil infiltration and goblet cell hyperplasia (P < 0.01), markedly lowered percentages of Treg cells and GATA3+ Treg cells in the spleen (P < 0.01), and increased expressions of IL-4, IL-6 and IL-10 (P < 0.05).@*CONCLUSION@#The percentage of GATA3+ Treg cells is decreased in AR patients and mouse models. GATA3+ Treg cells possibly participate in Th2 cell immune response, both of which are involved in the occurrence and progression of AR, suggesting the potential of GATA3+ Treg cells as a new therapeutic target for AR.


Subject(s)
Animals , Mice , Humans , Cytokines/metabolism , Disease Models, Animal , GATA3 Transcription Factor , Inflammation , Leukocytes, Mononuclear/metabolism , Mice, Inbred BALB C , Mice, Inbred C57BL , Nasal Mucosa/metabolism , Ovalbumin , Rhinitis, Allergic/therapy , T-Lymphocytes, Regulatory , Th2 Cells/metabolism
14.
Zhongguo zhenjiu ; (12): 522-526, 2023.
Article in Chinese | WPRIM | ID: wpr-980755

ABSTRACT

OBJECTIVE@#To observe the effect of modified acupuncture at sphenopalatine ganglion for allergic rhinitis (AR).@*METHODS@#A total of 80 patients with AR were randomly divided into an observation group and a control group, 40 cases in each group. In the observation group, modified acupuncture at sphenopalatine ganglion was given, 30 min each time, 2 times a week and with an interval of 3-4 days. In the control group, budesonide nasal spray was given. Both groups were treated for 4 weeks. The total nasal symptom score (TNSS) and total non-nasal symptom score (TNNSS) were observed before treatment, after first treatment, after last treatment and 4 weeks after treatment; the scores of visual analogue scale (VAS) and rhinoconjunctivitis quality of life questionnaire (RQLQ) were observed before treatment, after last treatment and 4 weeks after treatment; the recurrence condition was evaluated 4 weeks after treatment; the clinical efficacy was evaluated after last treatment in the two groups.@*RESULTS@#Compared with before treatment, the total scores and each score of TNSS, TNNSS scores after first treatment, after last treatment and 4 weeks after treatment were decreased in both groups (P<0.01, P<0.05). After first treatment, the total score, stuffy nose score, itchy nose score of TNSS and TNNSS score in the observation group were lower than the control group (P<0.01, P<0.05). After last treatment, the total score, stuffy nose score, itchy nose score of TNSS in the observation group were lower than the control group (P<0.01). Four weeks after treatment, the total score and each score of TNSS, TNNSS score in the observation group were lower than the control group (P<0.01, P<0.05). Compared with before treatment, the scores of VAS and RQLQ after last treatment and 4 weeks after treatment were decreased in both groups (P<0.01), and those in the observation group were lower than the control group (P<0.01). The recurrence rate was 13.5% (5/37) in the observation group, which was lower than 44.8% (13/29) in the control group (P<0.01). The total effective rate was 92.5% (37/40) in the observation group, which was higher than 72.5% (29/40) in the control group (P<0.05).@*CONCLUSION@#Modified acupuncture at sphenopalatine ganglion could effectively improve symptoms and quality of life in patients with AR, and the recurrence rate is lower.


Subject(s)
Humans , Quality of Life , Acupuncture Therapy , Rhinitis, Allergic/therapy , Pain Measurement
15.
Article in Chinese | WPRIM | ID: wpr-982732

ABSTRACT

Objective:To investigate the compliance of patients with allergic rhinitis(AR) receiving sublingual immunotherapy and its influencing factors. Methods:The clinical data of 291 AR patients who received sublingual immunotherapy for dust mites at the First Hospital of Peking University from January 2016 to January 2018 were retrospectively analyzed, and their outpatient or telephone follow-up was conducted. For patients whose treatment time was less than 2 years, the time and reason for the loss were recorded, and the factors affecting their compliance were discussed from the aspects of gender, age, and education. Results:Among the 291 patients, 245 cases(84.2%) were successfully followed up, and 193 cases(78.8%) fell off midway(treatment time<2 years). The overall compliance rate was 21.22%(52/245). The compliance rate of children is higher than that of adults(χ²=21.306, P<0.05), and gender and education level have no significant effect on the compliance rate. The time period for the largest number of shedding was 6-<12 months after treatment(68 cases, 27.8%). The main cause of shedding was symptom relief, which was considered cured(16.7%). Secondly, within 3 months after treatment, a total of 61 patients(24.9%) fell off, of which 34 cases(13.9%) fell off because of troublesome medication, often missed medication, and simply stopped taking the drug. Statistics on the overall reasons for shedding in 193 patients, the top three shedding reasons were: cured after symptom relief(59 cases, 30.6%), troublesome medication, discontinuation after missed dose(44 cases, 22.8%), slow onset or ineffectiveness(26 cases, 13.5%). Conclusion:The overall compliance of sublingual immunotherapy in patients with allergic rhinitis is poor, and the compliance of children is better than that of adults. Clinicians should focus on the reasons for patients to fall off at various times, strengthen patient education, enhance patient confidence in treatment, and improve the compliance of patients.


Subject(s)
Adult , Child , Animals , Humans , Sublingual Immunotherapy , Retrospective Studies , Treatment Outcome , Rhinitis, Allergic/drug therapy , Desensitization, Immunologic , Pyroglyphidae , Immunotherapy , Antigens, Dermatophagoides/therapeutic use
16.
Article in Chinese | WPRIM | ID: wpr-982749

ABSTRACT

Objective:To investigate the effect of posterior nasal neurectomy(PNN) with pharyngeal neurectomy (PN) on chronic sinusitis with nasal polyps (CRSwNP)complicated with perennial allergic rhinitis (PAR). Methods:83 patients with perennial allergic rhinitis combined with chronic group-wide sinusitis with nasal polyps who attended our hospital from July 2020 to July 2021 were selected. All patients underwent conventional functional endoscopic sinusitis surgery(FESS)+ nasal polypectomy. Patients were divided according to whether they underwent PNN+PN. 38 cases in the experimental group underwent FESS combined with PNN+PN; 44 cases in the control group underwent conventional FESS alone. All patients underwent the VAS, RQLQ, and MLK before treatment, and at 6 months and 1 year after surgery. Meanwhile, other relevant data were collected and the preoperative and postoperative follow-up data were collected and analyzed to assess the differences between the two groups. Results:The total postoperative follow-up period was 1 year. The recurrence rate of nasal polyps at 1 year postoperatively and the nasal congestion VAS score at 6 months postoperatively were not statistically significant in the two groups(P>0.05). However, the patients in the experimental group had statistically significantly lower effusion and sneezing VAS scores, MLK endoscopy scores and RQLQ scores at 6 months and 1 year postoperatively, and nasal congestion VAS scores at 1 year postoperatively compared to the control group(P<0.05). Conclusion:For patients with perennial AR complicated with CRSwNP, the combination of the PNN+PN in FESS can significantly improve the short-term curative effect, and PNN+PN is a safe and effective surgical treatment.


Subject(s)
Humans , Nasal Polyps/surgery , Rhinitis, Allergic/surgery , Sinusitis/surgery , Rhinitis, Allergic, Perennial , Endoscopy , Denervation , Chronic Disease , Rhinitis/complications
17.
Article in Chinese | WPRIM | ID: wpr-982753

ABSTRACT

Objective:To investigate the sensitization characteristics of ragweed pollen in patients with allergic rhinitis(AR) and(or) allergic asthma in Beijing area, and to provide basis for the prevention and treatment of ragweed pollen sensitized population. Methods:Patients with allergic rhinitis and/or asthma from January 2017 to December 2019 in the outpatient department of Allergy Department of Beijing Shijitan Hospital were retrospectively analyzed in this study. Skin prick test(SPT) was performed with ragweed pollen allergen reagents to compare different ages, genders and respiratory diseases allergen distribution, and to observe the sensitization characteristics of its population. All of the analyses were performed using SAS software version 9.4. Results:A total of 9 727 patients were enrolled in the end. The total positive rate of ragweed pollen SPT was 45.50%(4 426/9 727), the highest positive rate was 65.54% in 13-17 years old group; The positive rate of ragweed pollen SPT was 49.79% in allergic rhinitis combined with asthma patients, followed by 46.46% in allergic rhinitis patients, and the lowest rate was 19.42% in single allergic asthma patients. There were more females than males in both ragweed pollen sensitized and non-ragweed pollen sensitized groups(P<0.05), and the proportion was higher in 30-39 years old than in other age groups(P<0.05). Ragweed pollen sensitization was higher than non-ragweed pollen sensitization in the allergic rhinitis group(98.49% vs 94.76%, P<0.05). Ragweed pollen with other summer and autumn pollen allergens in patients with positive SPT, the top three were Chenopodium pollen, Humulus pollen and Artemisia grandis pollen, with positive rates of 90.42%, 89.63% and 85.40%, respectively. Ragweed combined with other pollen sensitization accounted for 99.57%(4 407/4 426). Allergic rhinitis was the main disease in patients sensitized with ragweed pollen alone or combined with other pollens, and there was no significant difference between the two groups(94.97% vs 98.50%, P>0.05). Conclusion:Ragweed pollen is highly sensitized in Beijing area, single ragweed pollen sensitization is rare, often combined with multiple pollen sensitization, and allergic rhinitis is the main disease.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Rhinitis, Allergic, Seasonal/epidemiology , Retrospective Studies , Allergens , Pollen , Rhinitis, Allergic , Asthma/epidemiology , Skin Tests
18.
Article in Chinese | WPRIM | ID: wpr-982760

ABSTRACT

The allergen nasal provocation testing(NPT), in which allergens are applied directly to the nasal mucosa under standard and controlled conditions to provoke the main symptoms of allergic rhinitis(AR), reproduces the response of the upper respiratory tract to natural exposure to allergens under controlled conditions and is the only test currently available to confirm nasal reactivity to allergens. It is invaluable in studying the mechanisms of AR and in assessing the response to novel anti-allergic treatments. The test may play an increasingly important role in clinical practice, especially in the identification of local AR, the diagnosis of occupational AR, the clarification of the composition of allergens, the assessment of the efficacy of AR treatment and the selection of candidates undergoing allergen immunotherapy. This article reviewed the application of NPT in the diagnosis of allergic and non-allergic rhinitis, and also introduces the indications, contraindications, advantages and limitations of NPT in evaluating nasal response.


Subject(s)
Humans , Allergens , Rhinitis/diagnosis , Nasal Provocation Tests , Rhinitis, Allergic/diagnosis , Nasal Mucosa
19.
Article in Chinese | WPRIM | ID: wpr-982761

ABSTRACT

Objective:To compare the clinical value of visual analogue scale (VAS), Lebel scale and total nasal symptom scores (TNSS) in evaluating nasal allergen provocation test (NAPT). Methods:A total of 151 patients suspected of allergic rhinitis admitted to the Department of Otolaryngology-Head and Neck Surgery of our hospital from April 2020 to September 2020 were included, of which 76 were positive for house dust mites and 75 were negative for allergens. Nasal airway resistance(NAR) was measured by active anterior nasal manometry. Nasal symptoms were evaluated by VAS, Lebel and TNSS. House dust mite allergen was used for NAPT by spray method. An increase≥40% in NAR was used as the gold standard for objective evaluation of NAPT. ROC curves of VAS, Lebel and TNSS were drawn to compare the evaluation effectiveness of different subjective evaluation methods, and the optimal critical point of each ROC curve was obtained. Results:With NAR increased by ≥40% as the gold standard, the area under ROC curve of VAS was 0.884, and the sensitivity and specificity were 97.75% and 80.65%, respectively. The area under ROC curve of Lebel was 0.773, and the sensitivity and specificity were 68.54% and 75.81%, respectively. The area under ROC curve of TNSS was 0.792, and the sensitivity and specificity were 68.54% and 79.03%, respectively. There was no significant difference between Lebel and TNSS(P>0.05). The VAS differed significantly from Lebel and TNSS(P<0.05). The Kappa values of VAS, Lebel, TNSS and NAR were 0.803, 0.432 and 0.459, respectively. Conclusion:The VAS, Lebel, TNSS subjective scale and NAR are consistent in evaluating the efficacy of NAPT, with the VAS assessment showing highest consistency with NAR. As objective assessment instruments are not widely used in China, subjective assessment method could be adopted to evaluate the efficacy of NAPT in clinical practice, and VAS scale is recommended as a priority.


Subject(s)
Animals , Humans , Allergens , Nasal Provocation Tests/methods , Rhinitis, Allergic/diagnosis , Nose , Pyroglyphidae
20.
Article in Chinese | WPRIM | ID: wpr-982762

ABSTRACT

Objective:To investigate the value of nasal provocation test(NPT) in evaluating the efficacy of allergen immunotherapy(AIT) in patients with dust mite induced allergic rhinitis(AR). Methods:A total of 83 patients with dust mite induced AR with/without asthma were included. Symptom score(SS), daily medication score(DMS), combined symptom and medication score(CSMS), rhinoconjunctivitis quality of life questionnaire(RQLQ), NPT and skin prick test(SPT) were assessed before and after 1 year AIT. Results:There were statistical differences in SS(P<0.000 1), DMS(P<0.000 1), CSMS(P<0.000 1), and RQLQ(P<0.000 1) after 1 year of AIT compared with pre-treatment. The effective rate of CSMS was 73.49%, and the effective rate of NPT was 42.17%. CSMS was consistent with NPT in efficacy assessment(Kappa=0.437, P<0.001); while in 54 patients with pre-treatment NPT concentrations other than the original concentration, CMSM and NPT showed better consistence(Kappa=0.895, P<0.001). Among the 48 patients with ineffective NPT assessment in the first year, 25 patients completed the second-year follow-up, and 12 patients(48.00%) showed effective in NPT. However, 10 out of 12 patients(83.33%) with NPT concentration other than original solution pre-treatment showed effective NPT at the second year. Conclusion:NPT can be used as one of the indicators for efficacy evaluation for dust mite induced AR patients, especially for patients with positive NPT induced at lower concentrations before treatment.


Subject(s)
Animals , Humans , Pyroglyphidae , Allergens , Nasal Provocation Tests , Quality of Life , Rhinitis, Allergic/therapy , Desensitization, Immunologic , Skin Tests , Dust
SELECTION OF CITATIONS
SEARCH DETAIL